Log in to save to my catalogue

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in pati...

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in pati...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_761c20eac4bf4e0f8dc9495fdeadff61

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non-randomized phase Ib/IIa trial, 32 HNSCC patients are treated with 2 doses (in weeks 1 and 3) of immune checkpoint blockade (ICB) using nivolumab (NIVO MONO, n = 6, phase Ib arm A) or nivolu...

Alternative Titles

Full title

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_761c20eac4bf4e0f8dc9495fdeadff61

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_761c20eac4bf4e0f8dc9495fdeadff61

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-021-26472-9

How to access this item